Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 5, 2010, Pages 418-429

  Landersdorfer, Cornelia B ^a,b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Diabetes; Insulin sensitivity; Mechanism based modeling; Pharmacodynamics; Pharmacokinetics

Indexed keywords

GLUCOSE; INSULIN; MONOCOMPONENT INSULIN;

ADULT; ARTICLE; CLAMP; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MATHEMATICAL ANALYSIS; PHARMACODYNAMICS; SINGLE DRUG DOSE; TURNOVER TIME; VOLUNTEER;

EID: 78449261791     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-017     Document Type: Article

References (47)

1. LeRoith, D.: Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med., 113 Suppl 6A: 3S-11S (2002).
2. Greenbaum, C. J.: Insulin resistance in type 1 diabetes. Diabetes Metab. Res. Rev., 18: 192-200 (2002).
3. Kjems, L. L., Christiansen, E., Volund, A., Bergman, R. N. and Madsbad, S.: Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes, 49: 580-588 (2000).
4. Monzillo, L. U. and Hamdy, O.: Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr. Rev., 61: 397-412 (2003).
5. DeFronzo, R. A., Tobin, J. D. and Andres, R.: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol., 237: E214-E223 (1979).
6. Muniyappa, R., Lee, S., Chen, H. and Quon, M. J.: Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab., 294: E15-E26 (2008).
7. Lee, S., Muniyappa, R., Yan, X., Chen, H., Yue, L. Q., Hong, E. G., Kim, J. K. and Quon, M. J.: Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am. J. Physiol. Endocrinol. Metab., 294: E261-E270 (2008).
8. Rave, K., Nosek, L., Heinemann, L., Gonzales, C., Ernest, C. S., Chien, J. and Muchmore, D.: Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and timeaction profiles. Diabet. Med., 21: 763-768 (2004).
9. Brunner, G. A., Balent, B., Ellmerer, M., Schaupp, L., Siebenhofer, A., Jendle, J. H., Okikawa, J. and Pieber, T. R.: Doseresponse relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia, 44: 305-308 (2001).
10. Arnolds, S. and Heise, T.: Inhaled insulin. Best Pract. Res. Clin. Endocrinol. Metab., 21: 555-571 (2007).
11. Black, C., Cummins, E., Royle, P., Philip, S. and Waugh, N.: The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol. Assess., 11: 1-126 (2007).
12. Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J. and Marchant, N.: Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics, 26: 217-234 (2008).
13. Rosenstock, J., Cefalu, W. T., Hollander, P. A., Belanger, A., Eliaschewitz, F. G., Gross, J. L., Klioze, S. S., St Aubin L. B., Foyt, H., Ogawa, M. and Duggan, W. T.: Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care, 31: 1723-1728 (2008).
14. White, N. H., Quattrin, T., St Aubin, L. B., Duggan, W. T., England, R. D. and Fryburg, J. S.: Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial. J. Pediatr. Endocrinol. Metab., 21: 555-568 (2008).
15. Roach, P.: New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin. Pharmacokinet., 47: 595-610 (2008).
16. Gopalakrishnan, M., Suarez, S., Hickey, A. J. and Gobburu, J. V.: Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J. Pharmacokinet. Pharmacodyn., 32: 485-500 (2005).
17. Dayneka, N. L., Garg, V. and Jusko, W. J.: Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm., 21: 457-478 (1993).
18. Beal, S. L., Boeckmann, A. J., Sheiner, L. B. and NONMEM Project Group.: NONMEM Users Guides. Version VI ed. San Francisco, University of California at San Francisco, 2007.
19. Bergman, R. N., Ider, Y. Z., Bowden, C. R. and Cobelli, C.: Quantitative estimation of insulin sensitivity. Am. J. Physiol., 236: E667-E677 (1979).
20. Mari, A.: Mathematical modeling in glucose metabolism and insulin secretion. Curr. Opin. Clin. Nutr. Metab. Care, 5: 495-501 (2002).
21. Krudys, K. M., Dodds, M. G., Nissen, S. M. and Vicini, P.: Integrated model of hepatic and peripheral glucose regulation for estimation of endogenous glucose production during the hot IVGTT. Am. J. Physiol. Endocrinol. Metab., 288: E1038-E1046 (2005).
22. Tornoe, C. W., Jacobsen, J. L. and Madsen, H.: Grey-box pharmacokinetic/ pharmacodynamic modelling of a euglycaemic clamp study. J. Math. Biol., 48: 591-604 (2004).
23. Woodworth, J. R., Howey, D. C. and Bowsher, R. R.: Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care, 17: 64-69 (1994).
24. Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D. and Ham, J.: Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther., 25: 358-371 (1979).
25. Miyazaki, M., Mukai, H., Iwanaga, K., Morimoto, K. and Kakemi, M.: Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability. J. Pharm. Pharmacol., 53: 1235-1246 (2001).
26. Brown, S. A., Nelson, R. W. and Bottoms, G. D.: Models for the pharmacokinetics and pharmacodynamics of insulin in alloxaninduced diabetic dogs. J. Pharm. Sci., 76: 295-299 (1987).
27. Colburn, W. A., Gottlieb, A. B., Koda, J. and Kolterman, O. G.: Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J. Clin. Pharmacol., 36: 13-24 (1996).
28. Rydberg, T., Jonsson, A., Karlsson, M. O. and Melander, A.: Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol., 43: 373-381 (1997).
29. Frey, N., Laveille, C., Paraire, M., Francillard, M., Holford, N. H. and Jochemsen, R.: Population PKPD modelling of the longterm hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br. J. Clin. Pharmacol., 55: 147-157 (2003).
30. Lin, S. and Chien, Y. W.: Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models. J. Pharm. Pharmacol., 54: 791-800 (2002).
31. Lee, S. H. and Kwon, K.I.: Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. Arch. Pharm. Res., 27: 806-810 (2004).
32. de Winter, W., DeJongh, J., Post, T., Ploeger, B., Urquhart, R., Moules, I., Eckland, D. and Danhof, M.: A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J. Pharmacokinet. Pharmacodyn., 33: 313-343 (2006).
33. Stepensky, D., Friedman, M., Raz, I. and Hoffman, A.: Pharmacokinetic- pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab. Dispos., 30: 861-868 (2002).
34. Benincosa, L. and Jusko, W. J.: Inventors: Novel Method of Treatment. World Intellectual Property Organization Publ. No. W0 00/27341. 1999.
35. Yun, H. Y., Park, H. C., Kang, W. and Kwon, K. I.: Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. J. Clin. Pharm. Ther., 31: 469-476 (2006).
36. Hamren, B., Bjork, E., Sunzel, M. and Karlsson, M.: Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin. Pharmacol. Ther., 84: 228-235 (2008).
37. Landersdorfer, C. B. and Jusko, W. J.: Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin. Pharmacokinet., 47: 417-448 (2008).
38. Silber, H. E., Jauslin, P. M., Frey, N., Gieschke, R., Simonsson, U. S. and Karlsson, M. O.: An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J. Clin. Pharmacol., 47: 1159-1171 (2007).
39. Amidi, M., Krudys, K. M., Snel, C. J., Crommelin, D. J., Della Pasqua, O. E., Hennink, W. E. and Jiskoot, W.: Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. J. Control Release, 127: 257-266 (2008).
40. Ferrannini, E. and Mari, A.: How to measure insulin sensitivity. J. Hypertens., 16: 895-906 (1998).
41. De Gaetano, A. and Arino, O.: Mathematical modelling of the intravenous glucose tolerance test. J. Math. Biol., 40: 136-168 (2000).
42. Cherrington, A. D., Neal, D. W., Edgerton, D. S., Glass, D., Bowen, L., Hobbs, C. H., Leach, C., Rosskamp, R. and Strack, T. R.: Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes, 53: 877-881 (2004).
43. Edgerton, D. S., Neal, D. W., Scott, M., Bowen, L., Wilson, W., Hobbs, C. H., Leach, C., Sivakumaran, S., Strack, T. R. and Cherrington, A. D.: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes, 54: 1164-1170 (2005).
44. Edgerton, D. S., Stettler, K. M., Neal, D. W., Scott, M., Bowen, L., Wilson, W., Hobbs, C. H., Leach, C., Strack, T. R. and Cherrington, A. D.: Inhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogs. J. Pharmacol. Exp. Ther., 319: 1258-1264 (2006).
45. Wolzt, M., de la Pena, A., Berclaz, P. Y., Tibaldi, F. S., Gates, J. R. and Muchmore, D. B.: AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care, 31: 735-740 (2008).
46. Kotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S. and Yki-Jarvinen, H.: Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology, 135: 122-130 (2008).
47. Patton, J. S., Bukar, J. G. and Eldon, M. A.: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet., 43: 781-801 (2004).